Moreover, knockout of either Anxa1 or Hmgb1 in MCA205 and TC1 cell abolished the tumor-growth reducing effect of the combination therapy with CDDP plus (R)-crizotinib (Supplementary Fig. 6j, m). Here, ANXA1 is linked to neoplasm.